MedTrace Logo

ELUCIDATE FFRct Study

NCT06018194 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 350

Last updated 2024-02-20

No results posted yet for this study

Summary

The goal of this study is to evaluate the diagnostic accuracy of a novel plaque-based coronary CT angiography (CCTA) fractional flow reserve (FFRct) software device for the estimation of invasive fractional flow reserve (FFR).

Researchers will compare the Elucid plaque-based FFRct analysis to invasively measured FFR in patients who have previously undergone CCTA and invasively assessed FFR.

Conditions

Interventions

DEVICE

ElucidVivo

Plaque morphology characterization on coronary CTA for predicting fractional flow reserve (FFRct)

Sponsors & Collaborators

  • Lundquist Institute at Harbor-UCLA Medical Center

    collaborator UNKNOWN

  • Elucid Bioimaging Inc.

    lead INDUSTRY

Principal Investigators

  • Ziad Ali, MD · Catholic Health - St. Francis Hospital

  • Todd C Villines, MD · Elucid Bioimaging Inc.

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-09-01
Primary Completion
2024-07-31
Completion
2024-07-31
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06018194 on ClinicalTrials.gov